Outlook Therapeutics (OTLK) Invested Capital: 2015-2020
Historic Invested Capital for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $11.0 million.
- Outlook Therapeutics' Invested Capital rose 7546.01% to $11.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $11.0 million, marking a year-over-year increase of 7546.01%. This contributed to the annual value of -$9.4 million for FY2019, which is 62.84% up from last year.
- As of Q2 2020, Outlook Therapeutics' Invested Capital stood at $11.0 million, which was up 153.43% from -$20.5 million recorded in Q1 2020.
- Outlook Therapeutics' Invested Capital's 5-year high stood at $11.0 million during Q2 2020, with a 5-year trough of -$35.3 million in Q1 2016.
- Moreover, its 3-year median value for Invested Capital was -$18.9 million (2018), whereas its average is -$13.4 million.
- In the last 5 years, Outlook Therapeutics' Invested Capital plummeted by 1,359.67% in 2017 and then surged by 7,546.01% in 2020.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Invested Capital stood at -$16.9 million in 2016, then increased by 23.68% to -$12.9 million in 2017, then slumped by 34.11% to -$17.3 million in 2018, then plummeted by 78.84% to -$30.9 million in 2019, then spiked by 7,546.01% to $11.0 million in 2020.
- Its last three reported values are $11.0 million in Q2 2020, -$20.5 million for Q1 2020, and -$30.9 million during Q4 2019.